Contribution of nationwide genome screening in Japan (LC-SCRUM-Japan) to the development of precision medicine for non-small cell lung cancer.Takashi Seto, Kōichi Goto, Takuma Yokoyama et al.|Journal of Clinical Oncology|2018Cited by 7
The efficacy of immune checkpoint inhibitors and PD-L1 status in patients with advanced non-small cell lung cancer harboring oncogenic driver alterations: Immuno-oncology biomarker study in LC-SCRUM-Japan.Kiyotaka Yoh, Kōichi Goto, Shingo Matsumoto et al.|Journal of Clinical Oncology|2019Cited by 5